Author

D. F. Robbiani

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5 Microbiology· 5 Biochemistry· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 12 Research Focus:host-pathogen & immune response· 11 Organism:human· 9 Assay:proteomics· 8 Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

M. C. Nussenzweig· 9 shared A. Gazumyan· 8 shared F. Muecksch· 8 shared T. Hatziioannou· 8 shared F. Schmidt· 7 shared M. Caskey· 7 shared P. D. Bieniasz· 7 shared Z. Wang· 7 shared

Activity by Year

2020-2024 · peak 9/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

9 shared papersMicrobiology

M. C. Nussenzweig

Mutual co-authors in cluster

Author profile →

12 papers

Recent·Most cited

Characterization of a novel humanized heavy chain antibody targeting endogenous retroviruses with anti-lymphoma activity

F. Spriano, L. Cascione, J. Sgrignani, N. Bendik, S. Napoli, G. Sartori, E. Cannas, T. Gong, A. J. Arribas, M. Pizzi, D. Rossi, D. F. Robbiani, A. Cavalli, F. Bertoni

This study identifies HERV-K as a therapeutic target in DLBCL, develops a humanized nanobody with anti-lymphoma activity, and shows its potential through antibody-dependent cytotoxicity.

bioRxiv · Jan 17, 2024 · PreprintCancer Biology

Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages

H. Marcotte, Y. Cao, F. Zuo, L. Simonelli, J. C. Sammartino, M. Pedotti, R. Sun, I. Cassaniti, M. Hagbom, A. Piralla, J. Yang, L. Du, E. Percivalle, F. Bertoglio, M. Schubert, , Q. Pan-Hammarstrom

Engineered dimeric and secretory IgA1 neutralized Omicron variants with higher potency than parental IgG.

Proceedings of the National Academy of Sciences · Jan 9, 2024Peer-reviewedMicrobiology

Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies

A. J. Greaney, T. N. Starr, C. O. Barnes, Y. Weisblum, F. Schmidt, M. Caskey, C. Gaebler, M. Agudelo, S. Finkin, Z. Wang, D. Poston, F. Muecksch, T. Hatziioannou, P. D. Bieniasz, D. F. Robbiani, , J. D. Bloom

The paper maps mutations in SARS-CoV-2 spike RBD that escape binding by three antibody classes and finds that plasma escape maps closely resemble those of a single antibody class targeting site E484.

bioRxiv · Mar 17, 2021Microbiology

Evolution of Antibody Immunity to SARS-CoV-2

C. Gaebler, Z. Wang, J. C. C. Lorenzi, F. Muecksch, S. Finkin, M. Tokuyama, A. Cho, M. Jankovic, D. Schaefer-Babajew, T. Y. Oliveira, M. Cipolla, C. Viant, C. O. Barnes, A. Hurley, M. Turroja, , R. Patel

This study examines the evolution of antibody immunity to SARS-CoV-2 over time, finding that memory B cells evolve with increased potency and resistance to mutations.

bioRxiv · Nov 3, 2020Immunology

Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo

A. Schaefer, F. Muecksch, J. C. C. Lorenzi, S. R. Leist, M. Cipolla, S. Bournazos, F. Schmidt, A. Gazumyan, R. S. Baric, D. F. Robbiani, T. Hatziioannou, J. V. Ravetch, P. D. Bieniasz, M. C. Nussenzweig, T. P. Sheahan

This study evaluates the in vivo protective efficacy of SARS-CoV-2 monoclonal antibodies, finding that in vitro potency does not always predict in vivo activity and that effector function and combinations are critical for protection.

bioRxiv · Sep 15, 2020Microbiology

Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro

Z. Wang, J. C. C. Lorenzi, F. Muecksch, S. Finkin, C. Viant, C. Gaebler, M. Cipolla, H.-H. Hoffman, T. Y. Oliveira, D. A. Oren, V. Ramos, L. Nogueira, E. Michailidis, D. F. Robbiani, A. Gazumyan, , M. C. Nussenzweig

This study shows that secretory IgA, particularly dimers, are more potent than IgG in neutralizing SARS-CoV-2 in vitro, suggesting their importance for mucosal protection and vaccine design.

bioRxiv · Sep 9, 2020 · PreprintImmunology

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Y. Weisblum, F. Schmidt, F. Zhang, J. DaSilva, D. Poston, J. C. C. Lorenzi, F. Muecksch, M. Rutkowska, H.-H. Hoffmann, E. Michailidis, C. Gaebler, M. Agudelo, A. Cho, Z. Wang, A. Gazumyan, , P. D. Bieniasz

The paper shows SARS-CoV-2 variants resistant to neutralizing antibodies can be selected and are present in circulating populations, suggesting the need for combination antibody therapies.

bioRxiv · Jul 21, 2020Microbiology

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

F. Schmidt, Y. Weisblum, F. Muecksch, H.-H. Hoffmann, E. Michailidis, J. C. C. Lorenzi, P. Mendoza, M. Rutkowska, E. Bednarski, C. Gaebler, M. Agudelo, A. Cho, Z. Wang, A. Gazumyan, M. Cipolla, , P. D. Bieniasz

The paper describes assays using pseudotyped and chimeric viruses to measure SARS-CoV-2 neutralizing antibody activity, showing correlation with authentic assays.

bioRxiv · Jun 8, 2020Microbiology

Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity

I. Lui, X. X. Zhou, S. A. Lim, S. Elledge, P. Solomon, N. J. Rettko, B. S. Zha, L. L. Kirkemo, J. A. Gramespacher, J. Liu, F. Muecksch, J. C. C. Lorenzi, F. Schmidt, Y. Weisblum, D. F. Robbiani, , J. A. Wells

This study investigates the interaction between SARS-CoV-2 Spike and ACE2, showing that dimeric ACE2 binds with high affinity to Spike and blocks viral entry, with limited intra-Spike avidity.

bioRxiv · May 21, 2020 · PreprintBiochemistry

Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals

D. F. Robbiani, C. Gaebler, F. Muecksch, J. Cetrulo Lorenzi, Z. Wang, A. Cho, M. Agudelo, C. Barnes, S. Finkin, T. Hagglof, T. Oliveira, C. Viant, A. Hurley, K. Millard, R. Kost, , Nuss

The paper analyzes antibody responses in convalescent individuals, finding low neutralizing titers but rare potent RBD-specific antibodies with broad antiviral potential.

bioRxiv · May 13, 2020Immunology

Public broadly neutralizing antibodies against hepatitis B virus in individuals with elite serologic activity

Q. Wang, E. Michailidis, Y. Yu, Z. Wang, A. M. Hurley, D. A. Oren, C. T. Mayer, A. Gazumyan, Z. Liu, Y. Zhou, T. Schoofs, K.-h. Yao, J. Nieke, J. Wu, Q. Jiang, , M. C. Nussenzweig

The paper identifies broadly neutralizing antibodies against HBV in elite neutralizers and shows that combinations of bNAbs targeting different epitopes are more effective than single bNAbs.

bioRxiv · Mar 4, 2020 · PreprintImmunology

A Combination of Two Human Monoclonal Antibodies Limits Fetal Damage by Zika Virus in Macaques

K. K. A. Van Rompay, L. L. Coffey, T. Kapoor, A. Gazumyan, R. I. Keesler, A. Jurado, A. Peace, M. Agudelo, J. Watanabe, J. Usachenko, A. Singapuri, R. Immareddy, A. Ardeshir, J. B. Stuart, S. Bournazos, , D. F. Robbiani

This study shows that two Fc-modified monoclonal antibodies limit fetal neurologic damage and vertical transmission of ZIKV in pregnant macaques.

bioRxiv · Jan 31, 2020Immunology